Kirsten M. Timms

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes”.

A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes

Nature Cancer(2022)10.1038/s43018-022-00439-1

N/A

3.5DataRank · unranked

132 citations

Anosheh Afghahi, Kirsten M. Timms, Alyssa DeWees, Wyatt Gross, Vasily N. Aushev +9 more

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology(2023)10.1016/s1470-2045(22)00739-2

N/A

2.0DataRank · unranked

102 citations

Priyanka Sharma, William E. Barlow, Julie R. Gralow, Shannon L. Puhalla, Carey K. Anders +16 more

Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer

Modern Pathology(2021)10.1038/s41379-020-00731-4

N/A

0.717DataRank · unranked

118 citations

Harsimar Kaur, Daniela C. Salles, Sanjana Murali, Edward M. Schaeffer, Jerry S. Lanchbury +8 more

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer

Cancers(2021)10.3390/cancers13050946

N/A

0.621DataRank · unranked

62 citations

Amir A. Jazaeri, Bryan Fellman, Molly S. Daniels, Suzanna Penn, Cara Solimeno +7 more

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1001

N/A

0.587DataRank · unranked

49 citations

Eve T. Rodler, William E. Barlow, Julie R. Gralow, Shannon Leigh Huggins-Puhalla, Carey K. Anders +15 more

Genomic and Clinicopathologic Characterization of ATM -deficient Prostate Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0764

N/A

0.564DataRank · unranked

42 citations

Daniela C. Salles, Sanjana Murali, Jessica Hicks, Minh Nguyen, Colin C. Pritchard +8 more

Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.525

N/A

0DataRank · unranked

0 citations

Lauren Lenz, Elizabeth S. Cogan, Erica L. Mayer, Virginia Kaklamani, Vered Stearns +15 more

Association of Genomic Instability Score, Tumor Mutational Burden, and Tumor-Infiltrating Lymphocytes as Biomarkers in Uterine Serous Carcinoma

Cancers(2023)10.3390/cancers15020528

N/A

0DataRank · unranked

1 citations

Pamela Peters, Regina S. Whitaker, Shonagh Russell, Benjamin B. Albright, Shelly Cummings +6 more